March 16 (Reuters) – BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients’ hip joint slipping out of place, the drugmaker said on Monday, sending its shares down 4%.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)
Comments